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ABSTRACT 
We studied the growth-promoting effect of treatment with recombinant human growth hormone 
in 23 pre-pubertal children with Noonan syndrome, aged between 5.4 and 14.3 y, and all with a 
height < 1.4 SD for Tanner standards. The growth response and skeletal maturation after 1 y of 
recombinant human growth hormone treatment (0.15 U/kg/day given by daily injection) in the 
Noonan syndrome patients was compared with the auxological changes observed in a group of 17 
girls with Turner syndrome with a comparable age and height deficit who were treated with 
recombinant human growth hormone in a similar way. During 1 y of treatment, the mean ± SD 
height velocity increased by 4.0 ± 1.6 cm/y in the Noonan syndrome group and by 3.6 ± 1.3 cm/y in 
the Turner syndrome group. Height SDS for chronological age in the Noonan syndrome group 
increased by 0.53 ± 0.46 (p < 0.001). In the Noonan syndrome patients the changes in height 
velocity were positively related to birthweight (r = 0.48, p < 0.05). The changes in height velocity or 
height SDS were not related to the age, height deficit or a delay in bone age maturation at start of 
treatment. In neither the patients with Noonan syndrome nor Turner syndrome was an 
acceleration of bone maturation found. We conclude that treatment with recombinant human 
growth hormone in pre-pubertal NS patients induces an increase in height velocity and height SDS 
comparable to that observed in Turner syndrome girls.
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Growth retardation involving both height and weight is a relatively consistent aspect of Noonan 
syndrome (NS) (1, 2). Adult height averages 162.5 ± 5.4cm in males and 152.7 ± 5.7 in females (2). 
Phenotypically, NS is strikingly similar to Turner syndrome (TS) and is therefore sometimes called 
the male TS. In girls with TS, treatment with supraphysiological doses of recombinant human 
growth hormone (rhGH) results in a clear-cut increase of height velocity and an amelioration of 
final height (3, 4). The similarity between NS and TS has led to the expectation that rhGH therapy in 
children with NS might also have a beneficial effect on growth rate and final height. 
Most reports on the effect of treatment with rhGH studied small groups of NS patients (5–8) only. 
Recently, growth hormone treatment data from the national Cooperative Growth Study in the US 
(150 patients with NS), and from the KIGS database in Europe (55 patients with NS) were published, 
reporting a significant sustained improvement of growth (9, 10). In the present study, we report 
first year auxological results of treatment with rhGH in a group of 23 NS children, and compare the 
data of the NS children with those observed in a group of rhGH-treated TS girls of comparable age 
and height deficit. 
Patients and methods 
Twenty-three children with NS (5F, 18M) followed in four university medical centres were included. 
Diagnosis of NS was made on the presence of typical phenotypic features. Typical facial changes 
were present in 22 patients, a congenital heart defect (most often pulmonary valve stenosis) in 15, 
and thorax deformity in 9 patients. Cryptorchidism was noted in 13 of the 18 males. Seven patients 
had one parent with NS. All patients had a score of ≥ 60 on the score of Duncan et al. (11) and had a 
normal karyotype. Inclusion criteria were a chronological age of at least 4 y, a height deficit of ≥ 2 
SDS for local standards, and a prepubertal status. The study protocol was approved by the local 
ethics committees, and informed consent was obtained from the parents. 
All patients were treated with daily subcutaneous injections of rhGH (Genotropin, Pharmacia & 
Upjohn, Sweden) at a dose of 0.15 IU/kg per day. The rhGH was given in the evening by means of a 
commercial pen system (KabiPen, Pharmacia & Upjohn). The calculated doses were rounded to the 
nearest 0.5 IU and adjusted to body weight every 3 months. No sex steroids were administered 
during the study period. 
Patients were followed-up at 3-monthly intervals. Height was measured with a Harpenden 
stadiometer. Height SDS was calculated using the reference standards of Tanner et al. (11). Height 
velocity was calculated over whole year periods and expressed as cm/y. Weight was expressed as 
body mass index (BMI, weight/length2). Puberty was assessed according to Tanner (13). At the start 
and after 1 y, bone age was determined using an X-ray of the left hand and wrist by an experienced 
observer (JDS) using the method of Greulich and Pyle (14). Biochemical analyses, including total 
blood count and glucose, haemoglobin-A1C, immunoreactive insulin, free thyroxine and thyroid 
stimulating hormone, were performed at 3-monthly intervals. 
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The auxological data of the NS patients were compared with those of a group of 17 girls with TS, 
who were followed at the same centres and treated in a similar way with daily rhGH (Norditropin, 
Novo Nordisk, Denmark) injections (15). None of the TS patients showed breast development, or 
was treated with sex steroids during the study period. Similar surveillance examinations as in NS 
patients under GH therapy were performed in these TS patients. The TS patients were selected by 
dose of GH administered and on age range (4–14.7 y) at the start of treatment to be comparable 
with the NS group studied. 
Results are expressed as mean ± SD. Inter-group comparisons were made with the unpaired 
Student’s t-test and intra-group comparisons were done with the paired Student’s t-test. The 
correlation between various parameters was studied by linear regression analysis. The level of 
significance was set at p < 0.05. 
Results 
Baseline data are given in Table 1. Birthweight and mid-parental height of patients with NS and TS 
were comparable. At start of treatment, no differences were found between the patient groups for 
CA, BA, BA delay, height SDS, and height velocity. The BMI, however, was lower in NS patients than 
in TS patients (15.1 ± 1.0 kg/m2 vs 17.6 ± 3.1 kg/m2; p < 0.01). There were no differences between NS 
patients with or without a cardiac anomaly (data not shown). 
Table 1. Baseline data (mean ± SD) and auxological data at the start of treatment with rhGH of patients with 
Noonan syndrome (NS) in comparison to patients with Turner syndrome (TS). 
 NS Group (n = 23) TS Group (n= 17) 
Birthweight (g) 2900 ± 694 2837 ± 607 
Midparental height (cm) 166.9 ± 7.4 167.1 ± 6.4 
Chronological age (y) 9.4 ± 3.0 9.2 ± 3.7 
Bone age (y) 7.2 ± 3.4 7.3 ± 3.7 
Bone age delay (y) 2.2 ± 1.0 1.9 ± 1.2 
Height (cm) 118.5 ± 14.5 115.5 ± 18.0 
Height SDS for CA −2.28 ± 0.68 −2.70 ±0.81 
Height SDS for BA 0.04 ± 1.50 −0.58 ± 1.50 
Weight (kg) 21.5 ± 5.8 25.0 ± 12.0 
Body Mass Index (kg/m2) 15.1 ± 1.0* 17.6 ± 3.2 
Height velocity (cm/y) 4.5 ± 1.0 4.4 ± 1.4 
*p < 0.01 
 
During the first year of rhGH treatment, height velocity of the NS patients increased from 4.5 ± 1.0 
cm/y to 8.5 ± 1.6 cm/y (Table 2). The increase in height velocity was comparable with the 
acceleration observed in TS girls (4.0 ± 1.6 cm/y vs 3.6 ± 1.3 cm/y, respectively). While the height 
velocity before and during treatment was negatively correlated with age at the start of treatment (r 
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= −0.60, p < 0.005 and r = −0.53, p < 0.01, respectively), the change in height velocity during 
treatment was not significantly related to age (r = −0.14). The increment in height velocity was 
significantly related to birthweight (r = 0.48, p < 0.05; Fig. 1), but not to any other baseline variables. 
Table 2. Auxological data (mean + SD) after 1 y of treatment with rhGH of patients with Noonan syndrome 
(NS) in comparison to patients with Turner syndrome (TS). 
 NS Group (n = 23) TS Group (n = 17) 
Chronological age (y) 10.3 ± 3.0 10.1 ± 3.7 
Bone age (y) 8.3 ± 3.4 8.8 ± 3.3 
Bone age delay (y) 2.0 ± 1.0 1.5 ± 1.2 
Height (cm) 127.1 ± 13.9 123.6 ± 16.5 
Height SDS for CA −1.78 ± 0.76 −2.11 ± 0.90 
Height SDS for BA 0.34 ± 1.50 −0.80 ± 1.26 
Weight (kg) 24.8 ± 6.5 −28.4 ± 12.5 
Body Mass Index (kg/m2) 15.1 ± 1.1* 17.7 ± 3.3 
Height velocity (cm/y) 8.5 ± 1.5 8.1 ± 1.7 
*p < 0.01 
 
Fig. 1. Changes in height velocity during the first year of rhGH treatment in patients with Noonan syndrome 
as a function of birthweight. 
 
 
Figure 2 illustrates the changes in height SDS for CA during 1 y of rhGH treatment in patients with 
NS (upper panel) and TS (lower panel). Mean increase of height SDS for CA was 0.53 ± 0.46 (p < 
0.001) in the NS patients and 0.59 ± 0.30 (p < 0.001) in the TS patients. At treatment start, height 
SDS for CA was > −2 SD for Tanner standards in 7 NS patients, whereas after 1 y of rhGH treatment 
14 had height > −2SD. The patients with NS showed an increase in height SDS for BA of 0.30 ± 0.63 
(p < 0.05) while height SDS for BA did not change in the TS patients (−0.13 ± 1.13). The changes in 
height SDS for BA and CA in NS patients were not statistically different from those observed in TS 
girls. In the NS patient the delta height SDS for BA was inversely related to the initial BA delay (r = — 
0.49, p < 0.02). The changes in height SDS for CA or BA were not related to any other baseline 
variables. 
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During rhGH therapy, BA in the NS group advanced from 7.2 ± 3.4 y to 8.3 ± 3.4 y and the BA delay 
did not change. The increase of 1.1 ± 0.4 y in the NS group was comparable to the change in 
skeletal maturation observed in TS girls (1.4 ± 0.9 y). The changes in skeletal maturation in the NS 
group were not related to age or any other baseline parameter. 
Fig. 2. Changes in height SDS for chronological age during 1 y of rhGH treatment in patients with NS (upper 
panel) and in girls with TS (lower panel). 
 
 
During rhGH treatment the NS and TS patients showed a weight gain of 3.4 ± 1.0 kg and 3.4 ± 1.7 kg, 
respectively. BMI, however, did not change. No differences were observed between NS patients 
with and without a cardiac anomaly. All patients remained pre-pubertal during the study period. 
No side effects were noted during rhGH therapy. No significant changes in chemical and 
haematological parameters were observed during the first year of treatment. All patients and 
parents desired to continue the treatment. 
Discussion 
In this study, we clearly show that daily administration of pharmacological doses of rhGH in pre-
pubertal children with NS increases height velocity and height SDS during the first year of 
treatment, while no acceleration of bone maturation was observed. In addition, we demonstrated 
that the response to rhGH therapy was comparable to that seen in girls with TS. 
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Although the prevalence of NS is higher than TS, only few studies on the growth-promoting effect 
of rhGH in NS have been published. Cianfarani et al. (5) studied three NS children who were treated 
with human GH in a dose of 0.1 IU/kg/day three times a week for 6–9 months and could not 
demonstrate any improvement of height velocity. Ahmed et al. (6), in contrast, using the same 
daily dose but given 6 days a week, observed a significant acceleration of height velocity after 1 y of 
treatment in five patients. Thomas et al. (7) observed that rhGH treatment in a daily dose of 0.15 
IU/kg/day, similar to our dosage regimen, in five NS children, started at a mean age of 3.9 y, 
resulted in a mean height increase from −3.3 to −2.4 SDS after a mean duration of 2.9 y. The 
experience from the Kabi International Growth Study (KIGS) of GH treatment in NS showed a 
significant increase in height SDS in NS patients treated for up to 3y, while the National 
Cooperative Growth Study in the US reported an increase for up to 4 y with rhGH (9, 10). The 
response was slightly better than observed in girls with TS. Municchi et al. (8) reported an increase 
in final height in three NS patients treated with rhGH (0.5 IU/kg/week) for at least 3 y. In line with 
these data from the literature, we observed an improvement of growth in our patients with NS. 
Moreover, we clearly demonstrated that the average first year growth response to rhGH treatment 
in pre-pubertal NS patients was comparable to that observed in TS girls treated with a similar 
treatment regimen. It remains, however, to be shown whether this treatment during the following 
years will finally result in an increase in final height, as reported in TS girls (3, 4). 
Compared to TS girls, the inter-individual variation in growth response was larger in the patients 
with NS. This cannot only be explained by the wide age range of the studied patients, since marked 
changes in height between patients were observed in young as well as older subjects. It is likely 
that the population of NS children included in this study, despite the fact that they all responded to 
a NS-specific scoring system, represents a heterogeneous group of disorders with different 
aetiologies and different growth histories, which might be reflected in disparate growth responses 
to rhGH administration. In this respect, it is important to remember that we observed a smaller 
growth response in those NS patients with a smaller birthweight suggesting that the degree of 
intrauterine growth retardation is one of the factors modulating the response to rhGH therapy. 
We found that skeletal maturation advanced slightly but not significantly slower during rhGH 
treatment in the NS group compared to TS girls. In untreated NS children Greulich and Pyle bone 
age determinations are, and continue to be, delayed by about 2 y after the age of 5 y compared to 
the normal population, inducing a delay of epiphyseal closure of about 2 y. In the TS girls, however, 
this delay in bone age increases steadily from the age of about 12 y, inducing a closure of the 
epiphyses probably after the age of 19 y (15). We confirmed in our NS group a delay in bone age of 
about 2.2 y, which did not change during rhGH treatment. All patients remained pre-pubertal 
during the study period and did not receive sex steroids or other drugs which might have 
influenced their skeletal maturation. 
This similar increment in height and bone age in NS patients makes rhGH treatment encouraging in 
obtaining a similar final height gain as in TS girls. However, we only showed similarities in the 
growth-stimulating effect of rhGH therapy between these two groups in pre-pubertal patients. This 
might not be the case during the pubertal period, since changes in bone age maturation and 
Published in : Acta Paediatrica (1997), vol. 68, pp. 943–946 




growth during the pubertal age period might be different in NS compared to TS patients, who 
develop spontaneous puberty (16) less frequently. It is clear that long-term studies of rhGH 
therapy, preferably when final height is reached, are necessary before the full value of rhGH 
treatment in NS can be assessed, but the first year results presented here are certainly 
encouraging. 
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